202 related articles for article (PubMed ID: 31089260)
1. H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas.
Cao T; Jiang Y; Wang Z; Zhang N; Al-Hendy A; Mamillapalli R; Kallen AN; Kodaman P; Taylor HS; Li D; Huang Y
Oncogene; 2019 Jul; 38(27):5356-5366. PubMed ID: 31089260
[TBL] [Abstract][Full Text] [Related]
2. RISING STARS: Role of MED12 mutation in the pathogenesis of uterine fibroids.
Ishikawa H; Kobayashi T; Kaneko M; Saito Y; Shozu M; Koga K
J Mol Endocrinol; 2023 Nov; 71(4):. PubMed ID: 37668348
[TBL] [Abstract][Full Text] [Related]
3. 3'RNA and whole-genome sequencing of archival uterine leiomyomas reveal a tumor subtype with chromosomal rearrangements affecting either HMGA2, HMGA1, or PLAG1.
Jokinen V; Mehine M; Reinikka S; Khamaiseh S; Ahvenainen T; Äyräväinen A; Härkki P; Bützow R; Pasanen A; Vahteristo P
Genes Chromosomes Cancer; 2023 Jan; 62(1):27-38. PubMed ID: 35822448
[TBL] [Abstract][Full Text] [Related]
4. Subtype-Specific Tumor-Associated Fibroblasts Contribute to the Pathogenesis of Uterine Leiomyoma.
Wu X; Serna VA; Thomas J; Qiang W; Blumenfeld ML; Kurita T
Cancer Res; 2017 Dec; 77(24):6891-6901. PubMed ID: 29055020
[TBL] [Abstract][Full Text] [Related]
5. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
6. The Mechanism and Function of Epigenetics in Uterine Leiomyoma Development.
Yang Q; Mas A; Diamond MP; Al-Hendy A
Reprod Sci; 2016 Feb; 23(2):163-75. PubMed ID: 25922306
[TBL] [Abstract][Full Text] [Related]
7. HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
Galindo LJ; Hernández-Beeftink T; Salas A; Jung Y; Reyes R; de Oca FM; Hernández M; Almeida TA
Gynecol Oncol; 2018 Sep; 150(3):562-568. PubMed ID: 30017537
[TBL] [Abstract][Full Text] [Related]
8. Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.
Commandeur AE; Styer AK; Teixeira JM
Hum Reprod Update; 2015; 21(5):593-615. PubMed ID: 26141720
[TBL] [Abstract][Full Text] [Related]
9. Altered chromatin landscape and enhancer engagement underlie transcriptional dysregulation in MED12 mutant uterine leiomyomas.
Moyo MB; Parker JB; Chakravarti D
Nat Commun; 2020 Feb; 11(1):1019. PubMed ID: 32094355
[TBL] [Abstract][Full Text] [Related]
10. Epigenomic and enhancer dysregulation in uterine leiomyomas.
Mlodawska OW; Saini P; Parker JB; Wei JJ; Bulun SE; Simon MA; Chakravarti D
Hum Reprod Update; 2022 Jun; 28(4):518-547. PubMed ID: 35199155
[TBL] [Abstract][Full Text] [Related]
11. Integrated data analysis reveals uterine leiomyoma subtypes with distinct driver pathways and biomarkers.
Mehine M; Kaasinen E; Heinonen HR; Mäkinen N; Kämpjärvi K; Sarvilinna N; Aavikko M; Vähärautio A; Pasanen A; Bützow R; Heikinheimo O; Sjöberg J; Pitkänen E; Vahteristo P; Aaltonen LA
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1315-20. PubMed ID: 26787895
[TBL] [Abstract][Full Text] [Related]
12. Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma.
Peng Y; Laser J; Shi G; Mittal K; Melamed J; Lee P; Wei JJ
Mol Cancer Res; 2008 Apr; 6(4):663-73. PubMed ID: 18403645
[TBL] [Abstract][Full Text] [Related]
13. Identification of Polycomb Group Protein EZH2-Mediated DNA Mismatch Repair Gene MSH2 in Human Uterine Fibroids.
Yang Q; Laknaur A; Elam L; Ismail N; Gavrilova-Jordan L; Lue J; Diamond MP; Al-Hendy A
Reprod Sci; 2016 Oct; 23(10):1314-25. PubMed ID: 27036951
[TBL] [Abstract][Full Text] [Related]
14. Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma.
Berta DG; Kuisma H; Välimäki N; Räisänen M; Jäntti M; Pasanen A; Karhu A; Kaukomaa J; Taira A; Cajuso T; Nieminen S; Penttinen RM; Ahonen S; Lehtonen R; Mehine M; Vahteristo P; Jalkanen J; Sahu B; Ravantti J; Mäkinen N; Rajamäki K; Palin K; Taipale J; Heikinheimo O; Bützow R; Kaasinen E; Aaltonen LA
Nature; 2021 Aug; 596(7872):398-403. PubMed ID: 34349258
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations.
Xie J; Ubango J; Ban Y; Chakravarti D; Kim JJ; Wei JJ
Genes Chromosomes Cancer; 2018 Oct; 57(10):485-494. PubMed ID: 29790226
[TBL] [Abstract][Full Text] [Related]
16. Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays.
Yatsenko SA; Mittal P; Wood-Trageser MA; Jones MW; Surti U; Edwards RP; Sood AK; Rajkovic A
Fertil Steril; 2017 Feb; 107(2):457-466.e9. PubMed ID: 27889101
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide DNA methylation analysis reveals a potential mechanism for the pathogenesis and development of uterine leiomyomas.
Maekawa R; Sato S; Yamagata Y; Asada H; Tamura I; Lee L; Okada M; Tamura H; Takaki E; Nakai A; Sugino N
PLoS One; 2013; 8(6):e66632. PubMed ID: 23818951
[TBL] [Abstract][Full Text] [Related]
18. MED12 exon 2 mutations in histopathological uterine leiomyoma variants.
Mäkinen N; Vahteristo P; Kämpjärvi K; Arola J; Bützow R; Aaltonen LA
Eur J Hum Genet; 2013 Nov; 21(11):1300-3. PubMed ID: 23443020
[TBL] [Abstract][Full Text] [Related]
19. Guizhi Fuling Capsule inhibits uterine fibroids growth by modulating Med12-mediated Wnt/β-Catenin signaling pathway.
Chen L; Chen H; Yang Q; Jiang Y; Liu L; Yu H; Chen Y; Li J; Chen N; Wang H; Wang Q
J Ethnopharmacol; 2022 May; 290():115115. PubMed ID: 35181487
[TBL] [Abstract][Full Text] [Related]
20. Long Noncoding RNA MIAT Modulates the Extracellular Matrix Deposition in Leiomyomas by Sponging MiR-29 Family.
Chuang TD; Quintanilla D; Boos D; Khorram O
Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34491311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
